Lantheus (NASDAQ: LNTH ) shares fell 25% after its Q1 2025 report. While it is never good to disappoint expectations and reduce EPS guidance for 2025, I think it is justified by M&A costs, divestitures of a low-growth segment andMy name is María Fernanda and I'm currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, so I look ...

LOS ANGELES, May 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of the securities laws. DJS Law Group INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Lantheus reported its financial results for the first quarter of 2025 on May 7, 2025. Along wit ...

Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Mark Kinarney - VP - Investor RelationsBrian Markison - CEO & DirectorPaul Blanchfield - PresidentAmanda Morgan - Chief Commercial OfficerRobert Marshall - CFO & TreasurerAnthony Petrone - Managing DirectorRichard Newitter - Managing DirectorMatthew Taylor - Managing DirectorYuan Zhi - Managing Director Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystNone - AnalystLarry Solow - Partn ...

Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good morning. Welcome to Lantheus First Quarter twenty twenty five Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's website approximately two hours after the completion of the call and will be archived for at least thirty days. I'll now turn the call over to Mark Kanarney, Vice President of Investor Relations. Mark? Speaker1 Thank yo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 | | ...

Exhibit 99.1 First Quarter 2025 Page 1 of 11 • Worldwide revenue of $372.8 million in the first quarter 2025 • GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 • Free cash flow totaled $98.8 million for the first quarter 2025 • Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the ...

Lantheus First Quarter 2025 Results May 7, 2025 © 2025 Lantheus. All rights reserved. 1 Agenda Highlights and Business Update Operational and Strategic Update Commercial Update Development Pipeline Update Financial Update Closing Remarks Q&A SPEAKERS Brian Markison CEO © 2025 Lantheus. All rights reserved. 2 Paul Blanchfield President Amanda Morgan Chief Commercial Officer Bob Marshall CFO and Treasurer Mark Kinarney Vice President, Investor Relations Safe Harbor Statements Cautionary Statement Regarding Fo ...

BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2025. "We are laying the foundation for the next chapter of Lantheus' business with the acquisition of Evergreen Theragnostics and planned acquisition of Life Molecular Imagin ...

Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business "This transaction enables Lantheus to concentrate our efforts on enhancing our radiopharmaceutical leadership focused on innovative diagnostics and therapeutics," said Brian Markison, CEO of Lantheus. "While the SPECT business has been a foundational part of Lantheus' nearly 70-year history, we believe it is the right time for this business and its outstanding employees to continue driving success ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. ("Evergreen"), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. Through the tra ...